RT Journal Article
T1 Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ('Registry').
A1 Erton, Zeynep Belce
A1 Sevim, Ecem
A1 de Jesús, Guilherme Ramires
A1 Cervera, Ricard
A1 Ji, Lanlan
A1 Pengo, Vittorio
A1 Ugarte, Amaia
A1 Andrade, Danieli
A1 Andreoli, Laura
A1 Atsumi, Tatsuya
A1 Fortin, Paul R
A1 Gerosa, Maria
A1 Zuo, Yu
A1 Petri, Michelle
A1 Sciascia, Savino
A1 Tektonidou, Maria G
A1 Aguirre-Zamorano, Maria Angeles
A1 Branch, D Ware
A1 Erkan, Doruk
A1 APS ACTION, 
K1 antibodies, anticardiolipin
K1 antibodies, antiphospholipid
K1 antiphospholipid syndrome
AB To describe the outcomes of pregnancies in antiphospholipid antibody (aPL)-positive patients since the inception of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Registry. We identified persistently aPL-positive patients recorded as 'pregnant' during prospective follow-up, and defined 'aPL-related outcome' as a composite of: (1) Preterm live delivery (PTLD) at or before 37th week due to pre-eclampsia (PEC), eclampsia, small-for-gestational age (SGA) and/or placental insufficiency (PI); or (2) Otherwise unexplained fetal death after the 10th week of gestation. The primary objective was to describe the characteristics of patients with and without aPL-related composite outcomes based on their first observed pregnancies following registry recruitment. Of the 55 first pregnancies observed after registry recruitment among nulliparous and multiparous participants, 15 (27%) resulted in early pregnancy loss  In our multicentre, international, aPL-positive cohort, of 55 first pregnancies observed prospectively, 15 (27%) were complicated by early pregnancy loss. Of the remaining 40 pregnancies, composite pregnancy morbidity was observed in 9 (23%) pregnancies.
SN 2053-8790
YR 2022
FD 2022
LK http://hdl.handle.net/10668/20164
UL http://hdl.handle.net/10668/20164
LA en
DS RISalud
RD Apr 6, 2025